| Min Pa: | Min Pa(max): | Activity's type: |
| Ext | Pa | Pi | Pmax | Activity | Other Results | ID Pa_max |
|---|---|---|---|---|---|---|
| 0.766 | 0.003 | 0.8 | 5 Hydroxytryptamine uptake inhibitor | 0.786 0.003 DBMET03704 0.648 0.004 DBMET03706 0.8 0.003 DBMET03708 0.721 0.003 DBMET03705 0.611 0.004 DBMET03707 | DBMET03708 | |
| 0.711 | 0.005 | 0.722 | HERG channel blocker | 0.622 0.007 DBMET03704 0.439 0.022 DBMET03706 0.722 0.005 DBMET03708 0.615 0.007 DBMET03705 0.433 0.023 DBMET03707 | DBMET03708 | |
| 0.692 | 0.005 | 0.694 | Potassium channel (Voltage-sensitive) blocker | 0.618 0.006 DBMET03704 0.454 0.019 DBMET03706 0.694 0.005 DBMET03708 0.599 0.007 DBMET03705 0.435 0.022 DBMET03707 | DBMET03708 | |
| 0.583 | 0.006 | 0.583 | Potassium channel blocker | 0.504 0.01 DBMET03704 0.519 0.01 DBMET03706 0.537 0.009 DBMET03708 0.468 0.014 DBMET03705 0.326 0.039 DBMET03707 | ||
| 0.501 | 0.004 | 0.501 | Histamine H1 receptor antagonist | 0.362 0.005 DBMET03704 0.089 0.049 DBMET03706 0.158 0.022 DBMET03708 0.251 0.009 DBMET03705 0.208 0.013 DBMET03707 | ||
| 0.436 | 0.053 | 0.568 | Antiobesity | 0.404 0.064 DBMET03704 0.289 0.124 DBMET03706 0.258 0.149 DBMET03708 0.416 0.06 DBMET03705 0.568 0.025 DBMET03707 | DBMET03707 | |
| 0.359 | 0.031 | 0.359 | Vasodilator | 0.323 0.041 DBMET03704 0.234 0.079 DBMET03706 0.18 0.122 DBMET03708 0.299 0.048 DBMET03705 0.338 0.037 DBMET03707 | ||
| 0.324 | 0.003 | 0.324 | Glycine transporter inhibitor | 0.262 0.003 DBMET03704 0.08 0.017 DBMET03706 0.108 0.01 DBMET03708 0.228 0.004 DBMET03705 0.142 0.006 DBMET03707 | ||
| 0.319 | 0.009 | 0.319 | Histamine antagonist | 0.247 0.014 DBMET03704 0.131 0.034 DBMET03705 | ||
| 0.315 | 0.009 | 0.315 | Antihistaminic | 0.246 0.014 DBMET03704 0.136 0.036 DBMET03705 | ||
| 0.309 | 0.035 | 0.309 | Ca(v)3.3 blocker | 0.277 0.065 DBMET03704 0.221 0.15 DBMET03706 0.206 0.179 DBMET03708 0.253 0.097 DBMET03705 | ||
| 0.282 | 0.012 | 0.282 | Butyrylcholinesterase inhibitor | 0.197 0.022 DBMET03704 0.092 0.068 DBMET03706 0.113 0.051 DBMET03708 0.156 0.032 DBMET03705 0.089 0.072 DBMET03707 | ||
| 0.253 | 0.003 | 0.253 | Glycine transporter 1 inhibitor | 0.206 0.004 DBMET03704 0.163 0.004 DBMET03706 0.153 0.004 DBMET03708 0.218 0.004 DBMET03705 0.164 0.004 DBMET03707 | ||
| 0.242 | 0.005 | 0.242 | Dopamine uptake inhibitor | 0.224 0.005 DBMET03704 0.051 0.048 DBMET03706 0.057 0.041 DBMET03708 0.13 0.013 DBMET03705 0.064 0.034 DBMET03707 | ||
| 0.212 | 0.005 | 0.381 | Adrenaline uptake inhibitor | 0.316 0.004 DBMET03704 0.087 0.023 DBMET03706 0.381 0.004 DBMET03708 0.15 0.009 DBMET03705 0.092 0.021 DBMET03707 | DBMET03708 | |
| 0.236 | 0.046 | 0.236 | P-glycoprotein inhibitor | 0.214 0.056 DBMET03704 0.156 0.108 DBMET03706 0.142 0.129 DBMET03708 0.186 0.074 DBMET03705 0.209 0.058 DBMET03707 | ||
| 0.181 | 0.005 | 0.299 | Progesterone antagonist | 0.168 0.005 DBMET03704 0.299 0.003 DBMET03706 0.096 0.009 DBMET03708 0.136 0.007 DBMET03705 0.28 0.004 DBMET03707 | DBMET03706 | |
| 0.156 | 0.014 | 0.165 | Alpha 1d adrenoreceptor antagonist | 0.165 0.013 DBMET03704 0.08 0.03 DBMET03705 | DBMET03704 | |
| 0.19 | 0.047 | 0.19 | Acetylcholine M1 receptor antagonist | 0.148 0.076 DBMET03704 0.148 0.077 DBMET03705 | ||
| 0.174 | 0.032 | 0.174 | 5 Hydroxytryptamine 2B antagonist | 0.129 0.052 DBMET03704 0.106 0.076 DBMET03705 | ||
| 0.174 | 0.038 | 0.259 | DNA polymerase I inhibitor | 0.165 0.041 DBMET03704 0.154 0.047 DBMET03706 0.129 0.062 DBMET03708 0.178 0.036 DBMET03705 0.259 0.016 DBMET03707 | DBMET03707 | |
| 0.174 | 0.042 | 0.174 | Acetylcholinesterase inhibitor | 0.131 0.069 DBMET03704 | ||
| 0.147 | 0.023 | 0.162 | Alpha 1b adrenoreceptor antagonist | 0.162 0.02 DBMET03704 0.079 0.046 DBMET03705 | DBMET03704 | |
| 0.161 | 0.045 | 0.161 | 5 Hydroxytryptamine antagonist | 0.131 0.059 DBMET03704 | ||
| 0.156 | 0.042 | 0.156 | 5 Hydroxytryptamine 2 antagonist | 0.137 0.05 DBMET03704 | ||
| 0.134 | 0.033 | 0.134 | Alpha 1 adrenoreceptor antagonist | 0.126 0.035 DBMET03704 | ||
| 0.253 | 0.162 | 0.358 | 15-Lipoxygenase inhibitor | 0.246 0.168 DBMET03704 0.271 0.149 DBMET03705 0.358 0.095 DBMET03707 | DBMET03707 | |
| 0.119 | 0.031 | 0.144 | Lanosterol 14 alpha demethylase inhibitor | 0.108 0.044 DBMET03704 0.144 0.014 DBMET03705 0.116 0.035 DBMET03707 | DBMET03705 | |
| 0.107 | 0.019 | 0.107 | 5 Hydroxytryptamine 1 agonist | 0.098 0.021 DBMET03704 0.071 0.028 DBMET03705 | ||
| 0.151 | 0.076 | 0.151 | Cholinergic | |||
| 0.111 | 0.041 | 0.111 | Calcium antagonist | |||
| 0.081 | 0.012 | 0.081 | Potassium channel (Inward rectifier) blocker | 0.067 0.019 DBMET03704 | ||
| 0.101 | 0.036 | 0.101 | Alpha 1a adrenoreceptor antagonist | 0.101 0.036 DBMET03704 | ||
| 0.125 | 0.062 | 0.125 | Acetylcholine muscarinic antagonist | |||
| 0.065 | 0.004 | 0.065 | Urotensin II agonist | 0.039 0.01 DBMET03704 0.028 0.017 DBMET03708 0.051 0.006 DBMET03705 0.042 0.009 DBMET03707 | ||
| 0.078 | 0.018 | 0.099 | Dopamine transporter inhibitor | 0.096 0.013 DBMET03704 0.099 0.012 DBMET03708 0.059 0.026 DBMET03705 | DBMET03708 | |
| 0.102 | 0.044 | 0.102 | 5 Hydroxytryptamine 2C antagonist | 0.09 0.053 DBMET03704 | ||
| 0.108 | 0.052 | 0.108 | Alpha adrenoreceptor antagonist | 0.103 0.055 DBMET03704 | ||
| 0.101 | 0.047 | 0.101 | Antineoplastic alkaloid | 0.085 0.059 DBMET03707 | ||
| 0.073 | 0.018 | 0.088 | 11-Beta-hydroxysteroid dehydrogenase 1 inhibitor | 0.059 0.023 DBMET03704 0.063 0.022 DBMET03706 0.041 0.039 DBMET03708 0.08 0.016 DBMET03705 0.088 0.014 DBMET03707 | DBMET03707 | |
| 0.071 | 0.019 | 0.071 | Histamine H3 receptor antagonist | 0.051 0.026 DBMET03704 | ||
| 0.072 | 0.019 | 0.072 | Neurokinin antagonist | 0.046 0.04 DBMET03704 0.049 0.035 DBMET03708 0.046 0.04 DBMET03705 | ||
| 0.064 | 0.017 | 0.086 | Mineralocorticoid receptor antagonist | 0.064 0.017 DBMET03704 0.072 0.014 DBMET03706 0.056 0.023 DBMET03708 0.079 0.012 DBMET03705 0.086 0.01 DBMET03707 | DBMET03707 | |
| 0.086 | 0.039 | 0.086 | 5 Hydroxytryptamine 1F antagonist | |||
| 0.059 | 0.015 | 0.059 | Neurokinin 1 antagonist | 0.038 0.032 DBMET03704 0.045 0.023 DBMET03708 0.038 0.032 DBMET03705 | ||
| 0.069 | 0.028 | 0.069 | Potassium channel intermediate-conductance Ca-activated blocker | 0.057 0.048 DBMET03706 0.068 0.029 DBMET03705 0.061 0.04 DBMET03707 | ||
| 0.091 | 0.052 | 0.091 | 5 Hydroxytryptamine 2A antagonist | 0.071 0.066 DBMET03704 | ||
| 0.052 | 0.015 | 0.052 | Substance P antagonist | 0.046 0.02 DBMET03708 | ||
| 0.11 | 0.074 | 0.11 | Sphingosine 1-phosphate receptor 2 agonist | |||
| 0.145 | 0.11 | 0.145 | ATPase inhibitor | 0.137 0.126 DBMET03704 | ||
| 0.176 | 0.144 | 0.176 | Cardiotonic | |||
| 0.166 | 0.141 | 0.166 | ErbB-1 antagonist | 0.16 0.155 DBMET03704 | ||
| 0.035 | 0.011 | 0.035 | Potassium channel (Inward rectifier) 1 blocker | 0.032 0.016 DBMET03704 0.032 0.017 DBMET03706 0.03 0.022 DBMET03708 0.033 0.014 DBMET03705 0.032 0.016 DBMET03707 | ||
| 0.168 | 0.144 | 0.169 | 5 Hydroxytryptamine 3E antagonist | 0.169 0.139 DBMET03704 | DBMET03704 | |
| 0.072 | 0.049 | 0.072 | Calcium channel L-type blocker | |||
| 0.196 | 0.173 | 0.289 | Transcription factor NF kappa B inhibitor | 0.233 0.14 DBMET03704 0.233 0.14 DBMET03706 0.239 0.135 DBMET03705 0.289 0.1 DBMET03707 | DBMET03707 | |
| 0.036 | 0.016 | 0.036 | Estrogen-related receptor beta antagonist | 0.031 0.025 DBMET03707 | ||
| 0.088 | 0.068 | 0.088 | MAO B inhibitor | |||
| 0.073 | 0.056 | 0.089 | Vanilloid 4 agonist | 0.089 0.027 DBMET03704 0.085 0.033 DBMET03707 | DBMET03704 | |
| 0.102 | 0.087 | 0.14 | Beta amyloid protein antagonist | 0.109 0.079 DBMET03704 0.134 0.053 DBMET03705 0.14 0.048 DBMET03707 | DBMET03707 | |
| 0.038 | 0.023 | 0.046 | 2,3-Oxidosqualene-lanosterol cyclase inhibitor | 0.046 0.014 DBMET03708 | DBMET03708 | |
| 0.055 | 0.046 | 0.055 | 5 Hydroxytryptamine 5 antagonist | |||
| 0.06 | 0.055 | 0.065 | 5 Hydroxytryptamine agonist | 0.065 0.051 DBMET03704 0.058 0.057 DBMET03705 | DBMET03704 | |
| 0.056 | 0.054 | 0.056 | 5 Hydroxytryptamine 5A antagonist | |||
| 0.036 | 0.035 | 0.036 | Neurokinin 2 antagonist | |||
| 0.091 | 0.093 | 0.148 | GABA C receptor antagonist | 0.148 0.031 DBMET03705 | DBMET03705 | |
| 0.082 | 0.088 | 0.12 | Topoisomerase I inhibitor | 0.12 0.056 DBMET03708 | DBMET03708 | |
| 0.03 | 0.038 | 0.16 | Kinesin-like protein 1 inhibitor | 0.16 0.005 DBMET03708 0.074 0.012 DBMET03705 | DBMET03708 | |
| 0.03 | 0.038 | 0.16 | Kinesin antagonist | 0.16 0.005 DBMET03708 0.074 0.012 DBMET03705 | DBMET03708 | |
| 0.061 | 0.069 | 0.065 | Secretase beta inhibitor | 0.064 0.063 DBMET03704 0.065 0.06 DBMET03705 | DBMET03705 | |
| 0.04 | 0.049 | 0.093 | Aldosterone antagonist | 0.043 0.042 DBMET03706 0.043 0.042 DBMET03705 0.093 0.009 DBMET03707 | DBMET03707 | |
| 0.053 | 0.068 | 0.072 | HIV-1 reverse transcriptase inhibitor | 0.071 0.048 DBMET03706 0.072 0.048 DBMET03707 | DBMET03707 | |
| 0.088 | 0.11 | 0.103 | Nav1.5 sodium channel blocker | 0.103 0.079 DBMET03704 0.099 0.086 DBMET03705 | DBMET03704 | |
| 0.074 | 0.097 | 0.123 | DNA directed RNA polymerase inhibitor | 0.123 0.035 DBMET03708 0.092 0.066 DBMET03707 | DBMET03708 | |
| 0.019 | 0.045 | 0.031 | Dipeptidyl peptidase I inhibitor | 0.031 0.02 DBMET03705 | DBMET03705 | |
| 0.037 | 0.068 | 0.053 | Parathyroid hormone antagonist | 0.046 0.03 DBMET03704 0.053 0.017 DBMET03705 | DBMET03705 | |
| 0.065 | 0.102 | 0.079 | Histamine H2 receptor antagonist | 0.079 0.067 DBMET03704 | DBMET03704 | |
| 0.03 | 0.069 | 0.049 | Vanilloid 3 antagonist | 0.037 0.031 DBMET03706 0.049 0.009 DBMET03707 | DBMET03707 | |
| 0.056 | 0.102 | 0.103 | Androgen antagonist | 0.103 0.044 DBMET03707 | DBMET03707 | |
| 0.038 | 0.086 | 0.06 | Androgen agonist | 0.06 0.041 DBMET03707 | DBMET03707 | |
| 0.159 | 0.208 | 0.175 | Neuropeptide Y2 antagonist | 0.175 0.171 DBMET03705 | DBMET03705 | |
| 0.008 | 0.06 | 0.043 | Prostaglandin H2 antagonist | 0.043 0.005 DBMET03707 | DBMET03707 | |
| 0.024 | 0.079 | 0.033 | Antibiotic Aminoglycoside-like | 0.033 0.031 DBMET03705 | DBMET03705 | |
| 0.068 | 0.13 | 0.101 | Nitric-oxide synthase inhibitor | 0.101 0.059 DBMET03704 0.1 0.06 DBMET03705 | DBMET03704 | |
| 0.066 | 0.133 | 0.514 | DNA intercalator | 0.514 0.005 DBMET03708 | DBMET03708 | |
| 0.113 | 0.185 | 0.189 | Lipocortins synthesis antagonist | 0.189 0.064 DBMET03707 | DBMET03707 | |
| 0.015 | 0.102 | 0.042 | Vascular adhesion protein 1 inhibitor | 0.042 0.022 DBMET03705 | DBMET03705 | |
| 0.009 | 0.1 | 0.027 | Glutamate (mGluR1a) agonist | 0.027 0.01 DBMET03707 | DBMET03707 | |
| 0.1 | 0.197 | 0.164 | Interferon gamma antagonist | 0.164 0.062 DBMET03707 | DBMET03707 | |
| 0.012 | 0.111 | 0.082 | Free fatty acid receptor 1 antagonist | 0.082 0.004 DBMET03707 | DBMET03707 | |
| 0.11 | 0.218 | 0.138 | Phospholipase C inhibitor | 0.138 0.134 DBMET03705 | DBMET03705 | |
| 0.018 | 0.127 | 0.089 | Thromboxane A2 antagonist | 0.089 0.011 DBMET03707 | DBMET03707 | |
| 0.013 | 0.125 | 0.037 | HMG CoA reductase inhibitor | 0.037 0.019 DBMET03707 | DBMET03707 | |
| 0.099 | 0.212 | 0.266 | Hypolipemic | 0.266 0.061 DBMET03707 | DBMET03707 | |
| 0.02 | 0.139 | 0.095 | Thromboxane antagonist | 0.095 0.013 DBMET03707 | DBMET03707 | |
| 0.154 | 0.277 | 0.215 | 5 Hydroxytryptamine uptake stimulant | 0.202 0.148 DBMET03705 0.215 0.124 DBMET03707 | DBMET03707 | |
| 0.12 | 0.248 | 0.309 | Lipoxygenase inhibitor | 0.309 0.067 DBMET03707 | DBMET03707 | |
| 0.062 | 0.203 | 0.103 | Glutamate (mGluR7) agonist | 0.103 0.055 DBMET03704 | DBMET03704 | |
| 0.037 | 0.181 | 0.109 | Macrophage migration inhibitory factor inhibitor | 0.109 0.03 DBMET03707 | DBMET03707 | |
| 0.057 | 0.205 | 0.113 | Nav1.4 sodium channel blocker | 0.113 0.059 DBMET03705 | DBMET03705 | |
| 0.153 | 0.306 | 0.252 | Analgesic | 0.252 0.181 DBMET03704 | DBMET03704 | |
| 0.024 | 0.184 | 0.072 | Sphingosine 1-phosphate receptor 4 agonist | 0.072 0.043 DBMET03707 | DBMET03707 | |
| 0.087 | 0.253 | 0.185 | Non-steroidal antiinflammatory agent | 0.185 0.084 DBMET03707 | DBMET03707 | |
| 0.043 | 0.217 | 0.148 | Uric acid excretion stimulant | 0.105 0.049 DBMET03706 0.148 0.024 DBMET03707 | DBMET03707 | |
| 0.023 | 0.198 | 0.083 | Glutamate receptor agonist | 0.083 0.05 DBMET03707 | DBMET03707 | |
| 0.064 | 0.253 | 0.127 | Diuretic | 0.127 0.097 DBMET03707 | DBMET03707 | |
| 0.013 | 0.204 | 0.041 | Somatostatin 5 agonist | 0.041 0.017 DBMET03705 | DBMET03705 | |
| 0.055 | 0.249 | 0.128 | DOPA decarboxylase inhibitor | 0.128 0.037 DBMET03707 | DBMET03707 | |
| 0.008 | 0.203 | 0.038 | Sphingosine 1-phosphate receptor 1 agonist | 0.038 0.036 DBMET03707 | DBMET03707 | |
| 0.003 | 0.203 | 0.029 | Prostaglandin E2 agonist | 0.029 0.011 DBMET03707 | DBMET03707 | |
| 0.013 | 0.227 | 0.04 | Sphingosine 1-phosphate receptor agonist | 0.04 0.037 DBMET03707 | DBMET03707 | |
| 0.002 | 0.218 | 0.023 | G-protein-coupled receptor 120 agonist | 0.023 0.008 DBMET03707 | DBMET03707 | |
| 0.018 | 0.234 | 0.042 | ATM kinase inhibitor | 0.042 0.014 DBMET03708 | DBMET03708 | |
| 0.004 | 0.22 | 0.023 | Prostaglandin D2 antagonist | 0.023 0.016 DBMET03707 | DBMET03707 | |
| 0.024 | 0.249 | 0.054 | Cathepsin B inhibitor | 0.054 0.042 DBMET03706 | DBMET03706 | |
| 0.005 | 0.239 | 0.037 | Prostaglandin agonist | 0.037 0.015 DBMET03707 | DBMET03707 | |
| 0.02 | 0.261 | 0.07 | Sphingosine 1-phosphate receptor 5 agonist | 0.07 0.017 DBMET03707 | DBMET03707 | |
| 0.095 | 0.347 | 0.233 | Cholesterol antagonist | 0.233 0.138 DBMET03707 | DBMET03707 | |
| 0.028 | 0.284 | 0.082 | Ornithine decarboxylase inhibitor | 0.082 0.065 DBMET03707 | DBMET03707 | |
| 0.01 | 0.267 | 0.107 | Prostaglandin antagonist | 0.107 0.016 DBMET03707 | DBMET03707 | |
| 0.043 | 0.338 | 0.109 | Aldehyde dehydrogenase inhibitor | 0.109 0.085 DBMET03706 | DBMET03706 | |
| 0.011 | 0.311 | 0.082 | Peroxisome proliferator-activated receptor gamma agonist | 0.082 0.039 DBMET03707 | DBMET03707 | |
| 0.027 | 0.365 | 0.069 | Keratolytic | 0.069 0.068 DBMET03707 | DBMET03707 | |
| 0.003 | 0.346 | 0.039 | Free fatty acid receptor 1 agonist | 0.039 0.005 DBMET03707 | DBMET03707 | |
| 0.109 | 0.453 | 0.49 | Cyclophilin D inhibitor | 0.49 0.053 DBMET03707 | DBMET03707 | |
| 0.122 | 0.473 | 0.34 | Antiinflammatory | 0.34 0.18 DBMET03707 | DBMET03707 | |
| 0.054 | 0.406 | 0.125 | Melanin inhibitor | 0.125 0.123 DBMET03707 | DBMET03707 | |
| 0.004 | 0.375 | 0.032 | Prostaglandin EP3 antagonist | 0.032 0.019 DBMET03707 | DBMET03707 | |
| 0.029 | 0.41 | 0.088 | Triose-phosphate isomerase inhibitor | 0.088 0.063 DBMET03707 | DBMET03707 | |
| 0.023 | 0.409 | 0.135 | Ferrochelatase inhibitor | 0.135 0.045 DBMET03707 | DBMET03707 | |
| 0.021 | 0.409 | 0.054 | Leukotriene C antagonist | 0.054 0.046 DBMET03707 | DBMET03707 | |
| 0.004 | 0.391 | 0.04 | Urate transporter 1 inhibitor | 0.04 0.026 DBMET03707 | DBMET03707 | |
| 0.094 | 0.482 | 0.184 | Tyrosine 3 hydroxylase inhibitor | 0.184 0.166 DBMET03707 | DBMET03707 | |
| 0.008 | 0.454 | 0.06 | Check point kinase 1 inhibitor | 0.06 0.059 DBMET03708 | DBMET03708 | |
| 0.048 | 0.507 | 0.169 | Factor V inhibitor | 0.169 0.011 DBMET03706 | DBMET03706 | |
| 0.004 | 0.486 | 0.032 | Calpain 1 inhibitor | 0.032 0.027 DBMET03706 | DBMET03706 | |
| 0.03 | 0.542 | 0.104 | ABCA1 expression enhancer | 0.104 0.045 DBMET03706 | DBMET03706 | |
| 0.023 | 0.544 | 0.204 | Platelet antagonist | 0.204 0.098 DBMET03707 | DBMET03707 | |
| 0.031 | 0.582 | 0.089 | 3C-Like protease (SARS coronavirus) inhibitor | 0.089 0.048 DBMET03706 | DBMET03706 | |
| 0.032 | 0.691 | 0.196 | Hypoglycemic | 0.196 0.116 DBMET03707 | DBMET03707 | |
| 0.004 | 0.678 | 0.052 | Prostaglandin EP2 antagonist | 0.052 0.05 DBMET03707 | DBMET03707 | |
| 0.051 | 0.814 | 0.204 | Interleukin 2 agonist | 0.204 0.182 DBMET03705 | DBMET03705 | |
| 0.063 | 0.857 | 0.37 | Calcium channel L-type activator | 0.37 0.103 DBMET03704 | DBMET03704 | Ext | Pa | Pi | Pmax | Activity | Other Results | ID Pa_max |